Physician profile
Umar Murad
NPI 1952391724
$1,999.13
in general payments reported to CMS, 2019-2025
27 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $201 · 2021: $283 · 2022: $415 · 2023: $177 · 2024: $169 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $432.49 | 2019-2023 | |
| Lilly USA, LLC | $314.50 | 2020-2023 | Jardiance |
| Corium, LLC | $152.91 | 2023-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $109.80 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.54 | 2025 | Caplyta |
| Amgen INC. | $72.67 | 2019-2025 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.33 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $63.06 | 2019-2020 | |
| Novo Nordisk INC | $60.84 | 2025 | Ozempic |
| Esperion Therapeutics, INC. | $54.38 | 2020-2021 | |
| Allergan, INC. | $52.60 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $52.55 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $48.45 | 2023-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $47.51 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $43.96 | 2024-2025 | Uzedy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $43.28 | 2019 | |
| Abbvie INC. | $40.66 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $38.37 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Bayer Healthcare Pharmaceuticals INC. | $36.27 | 2022-2023 | |
| Pfizer INC. | $28.99 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $28.58 | 2025 | Voquezna |
| Inogen, INC. | $24.61 | 2022 | |
| Neurocrine Biosciences, INC. | $19.96 | 2025 | |
| Merck Sharp & Dohme LLC | $18.24 | 2022 | |
| Exact Sciences Corporation | $16.13 | 2025 | The Cologuard Plus Collection Kit |
| Alkermes, INC. | $16.06 | 2024 | Vivitrol |
| Dexcom, INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umar Murad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.